Alterola Biotech, Inc. (ABTI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.43: the stock has moved about 43% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAlterola Biotech, Inc. (ABTI) trades at $0.0002. Alterola Biotech, Inc. is a UK-based pharmaceutical company specializing in the development of regulated cannabinoid and cannabinoid-like molecules. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for ABTI: ABTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Alterola Biotech, Inc. (ABTI) Healthcare & Pipeline Overview
Alterola Biotech, Inc. is a UK-based pharmaceutical company specializing in the development of cannabinoid and cannabinoid-like molecules. It focuses on creating regulated human and animal health pharmaceuticals, as well as food products. The company also engages in active pharmaceutical ingredient production and advanced drug delivery formulation, aiming to enhance bioavailability, solubility, and stability within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for ABTI?
Alterola Biotech, Inc. presents an investment thesis centered on its specialized focus within the evolving cannabinoid therapeutics market. The company's strategy to develop regulated human and animal health pharmaceuticals, alongside regulated food products, positions it to capitalize on increasing acceptance and scientific understanding of cannabinoids. Its integrated approach, encompassing API production and advanced formulation techniques for improved bioavailability, solubility, and stability, could differentiate it in a competitive landscape. While operating with a lean structure of one employee and a market capitalization of $0.01 billion, indicating an early-stage or micro-cap profile, the potential for significant value creation hinges on successful clinical development and regulatory approvals for its pipeline candidates. Key catalysts would include progress in clinical trials, securing intellectual property, and achieving regulatory milestones, particularly in the UK or other major markets. The beta of 1.43 suggests higher volatility compared to the broader market, reflecting the inherent risks of a development-stage pharmaceutical company. The absence of a dividend indicates a focus on reinvestment into research and development.
Based on FMP financials and quantitative analysis
ABTI Key Highlights
Market Capitalization: $0.01 billion, reflecting its micro-cap status within the pharmaceutical sector.
- Beta: 1.43, indicating higher volatility relative to the broader market, typical for development-stage biotech firms.
- Dividend Yield: None, as the company does not currently pay dividends, suggesting reinvestment of capital into R&D and operational growth.
- Employee Count: 1 employee, highlighting a highly lean operational structure for a pharmaceutical development company.
- Strategic Focus: Specialization in cannabinoid and cannabinoid-like molecule development for regulated human/animal health pharmaceuticals and food products.
Who Are ABTI's Competitors?
ABTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABTI's Key Strengths?
Specialized focus on cannabinoid and cannabinoid-like molecules, a growing therapeutic area.
- Integrated capabilities in API production and formulation development.
- Commitment to regulated product development across human, animal, and food sectors.
- Lean operational structure with a focused R&D approach.
What Are ABTI's Weaknesses?
Micro-cap status ($0.01B market cap) and single employee indicate very early stage or limited resources.
- High beta (1.43) suggests significant market volatility and risk.
- "Unknown" disclosure status on OTC market raises transparency concerns.
- Reliance on successful R&D and regulatory approvals in a highly competitive and regulated industry.
What Are the Key Risks for ABTI?
Financial-distress signal — its Altman Z-Score of -43.65 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-14.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory Uncertainty: The evolving and often complex regulatory landscape surrounding cannabinoid-based products poses a significant risk to product development and market access.
- Clinical Development Failure: High risk inherent in pharmaceutical R&D, where compounds may fail to demonstrate efficacy or safety in trials, leading to significant financial losses.
- Capital Constraints: As a micro-cap company with limited employees, Alterola Biotech may face challenges in securing sufficient funding for extensive R&D and commercialization efforts.
- Intense Competition: The cannabinoid market is attracting significant interest, leading to competition from well-funded established pharmaceutical companies and other biotech firms.
- OTC Market Risks: Trading on the "OTC Other" tier with "Unknown" disclosure status exposes investors to risks of illiquidity, lack of transparency, and potential for price manipulation.
What Threats Does ABTI Face?
- Intense regulatory scrutiny and evolving legal landscape for cannabinoid products.
- Competition from larger pharmaceutical companies and well-funded biotech firms.
- Clinical trial failures or delays in regulatory approvals.
- Capital constraints typical for early-stage biotech companies, especially with a small market cap.
What Are ABTI's Competitive Advantages?
- Specialized Focus: Deep expertise in cannabinoid and cannabinoid-like molecule development, a niche with high barriers to entry due to regulatory complexity.
- Integrated Capabilities: In-house production of APIs and food-grade ingredients provides control over quality and supply chain, potentially reducing costs.
- Formulation & Delivery Innovation: Focus on improving bioavailability, solubility, and stability could lead to proprietary drug delivery systems and enhanced product efficacy.
- Regulatory Compliance Emphasis: Commitment to developing "regulated" products for human, animal, and food applications positions the company for market acceptance in a highly scrutinized industry.
What Does ABTI Do?
Alterola Biotech, Inc. is a pharmaceutical company headquartered in Birkenhead, United Kingdom, dedicated to advancing the field of cannabinoid and cannabinoid-like molecule development. Established to address specific therapeutic and nutritional needs, the company's operational framework encompasses several critical areas within the drug manufacturing sector. Its core mission revolves around the rigorous development of regulated pharmaceuticals for both human and animal health applications, ensuring compliance with stringent industry standards. This involves a comprehensive approach from initial research to final product formulation. Beyond therapeutic development, Alterola Biotech is also strategically involved in the creation of regulated food products, leveraging its expertise in cannabinoid science to explore novel applications in the nutraceutical space. A significant aspect of its business model includes the in-house production of active pharmaceutical ingredients (APIs) and food-grade ingredients. This vertical integration allows for greater control over quality, supply chain, and cost efficiencies, which are crucial in the highly regulated pharmaceutical and food industries. Furthermore, the company places a strong emphasis on innovative formulation and drug delivery technologies. Its research and development efforts are geared towards improving the bioavailability, solubility, and stability of its cannabinoid-based compounds. This focus is critical for enhancing therapeutic efficacy, reducing dosing requirements, and improving patient compliance. Operating with a lean structure, the company employs a focused strategy to navigate the complex landscape of cannabinoid research and commercialization, aiming to carve out a niche in the specialty and generic drug manufacturing industry through its specialized expertise and integrated capabilities.
What Products and Services Does ABTI Offer?
- Develops cannabinoid and cannabinoid-like molecules for pharmaceutical applications.
- Focuses on creating regulated human health pharmaceuticals.
- Engages in the development of regulated animal health pharmaceuticals.
- Produces regulated food products utilizing cannabinoid compounds.
- Manufactures active pharmaceutical ingredients (APIs) in-house.
- Produces food-grade ingredients for its product lines.
- Conducts research and development on formulation and drug delivery technologies.
- Aims to improve the bioavailability, solubility, and stability of its compounds.
How Does ABTI Make Money?
- Research & Development: Invests in the discovery and development of novel cannabinoid-based molecules and formulations.
- Product Commercialization: Seeks to generate revenue through the sale of regulated human and animal health pharmaceuticals and food products upon successful development and regulatory approval.
- Ingredient Production: Potentially generates revenue by producing and supplying active pharmaceutical ingredients (APIs) and food-grade ingredients, either for internal use or external sales.
What Industry Does ABTI Operate In?
Alterola Biotech, Inc. operates within the "Drug Manufacturers - Specialty & Generic" industry, a segment of the broader Healthcare sector. This industry is characterized by intense research and development, stringent regulatory oversight, and a high demand for innovative therapeutic solutions. Alterola Biotech specifically targets the burgeoning market for cannabinoid and cannabinoid-like molecules, a niche experiencing significant scientific interest and evolving regulatory frameworks globally. The global cannabis therapeutics market, while still maturing, is projected to grow substantially, driven by increasing legalization and clinical evidence supporting various applications. Alterola's focus on regulated products, API production, and advanced drug delivery positions it to address specific unmet needs within this specialized segment. Competition includes both established pharmaceutical giants exploring cannabinoid applications and a growing number of smaller biotech firms. Alterola's lean structure and specialized focus aim to carve out a distinct position by emphasizing regulated development and formulation expertise.
Who Are ABTI's Key Customers?
- Healthcare providers and patients (indirectly, through pharmaceutical products).
- Veterinary clinics and animal owners (indirectly, through animal health products).
- Consumers seeking regulated cannabinoid-infused food products.
- Potentially other pharmaceutical or nutraceutical companies requiring specialized cannabinoid APIs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Alterola Biotech, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Birkenhead, GB. The company is led by CEO David John Hitchcock. ABTI has traded publicly since 2010.
Key Financial Metrics
Return on equity for Alterola Biotech, Inc. stands at -14.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -37.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Alterola Biotech, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -43.65 places it in the distress zone, a signal of elevated financial risk.
ABTI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ABTI Latest News
No recent news available for ABTI.
ABTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ABTI.
Price Targets
Wall Street price target analysis for ABTI.
ABTI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ABTI; grades run from A+ (80-100) to F (below 30).
Leadership: David John Hitchcock
Chief Executive Officer
David John Hitchcock leads Alterola Biotech, Inc., a pharmaceutical company focused on cannabinoid and cannabinoid-like molecule development. His role involves overseeing the strategic direction and operational execution for a lean organization of one employee. His responsibilities encompass guiding the production of active pharmaceutical ingredients and food-grade ingredients, alongside spearheading research into advanced formulation and drug delivery methods aimed at improving compound bioavailability, solubility, and stability.
Track Record: Under David John Hitchcock's leadership, Alterola Biotech, Inc. has established a clear strategic focus on the specialized development of regulated cannabinoid-based products. Key milestones include the ongoing efforts in developing pharmaceuticals for both human and animal health, alongside regulated food products. His management has also prioritized the integration of in-house API production and advanced formulation techniques, which are critical for controlling quality and enhancing product efficacy. These strategic decisions underscore the company's commitment to navigating the complex regulatory landscape of the cannabinoid industry.
ABTI OTC Market Information
Alterola Biotech, Inc. trades on the OTC market under the "OTC Other" tier. This designation typically applies to companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, or major exchanges such as the NYSE or NASDAQ. Companies in the "OTC Other" tier are not required to report to the SEC, meaning their financial disclosures can be less frequent, less detailed, or entirely absent, leading to significantly lower transparency compared to exchange-listed or even higher-tier OTC stocks. This tier often includes shell companies, distressed companies, or those with limited public information, making due diligence more challenging for investors.
- OTC Tier: OTC Other
- Limited Disclosure: "Unknown" disclosure status means a severe lack of financial and operational transparency, hindering informed investment decisions.
- Extreme Illiquidity: Very low trading volume and wide bid-ask spreads make it difficult to buy or sell shares without significantly impacting the price.
- Regulatory Scrutiny: OTC Other companies face less regulatory oversight, which can expose investors to higher risks of fraud or manipulation.
- Price Volatility: Small market capitalization and low liquidity can lead to extreme price fluctuations based on minimal trading activity.
- Difficulty in Valuation: Lack of reliable financial data makes fundamental valuation extremely challenging, relying heavily on speculation.
- Verify any available financial statements directly from the company or third-party sources, if possible.
- Research management's background and track record beyond what is publicly stated.
- Investigate any legal or regulatory actions against the company or its leadership.
- Assess the actual progress of their product development pipeline and intellectual property.
- Examine any press releases or company communications for substantive updates.
- Understand the specific regulatory environment for cannabinoid products in the UK and target markets.
- Evaluate the company's capital structure and potential need for future financing.
- Stated Business Focus: A clear description of engaging in pharmaceutical development of cannabinoid molecules.
- Headquarters Location: Located in Birkenhead, UK, indicating a physical presence in a regulated jurisdiction.
- Named Leadership: David John Hitchcock is identified as the individual managing the company.
Common Questions About ABTI (Healthcare)
What are the key growth opportunities for ABTI in healthcare?
Alterola Biotech, Inc. has several key growth opportunities within the healthcare sector, primarily driven by its specialized focus on cannabinoid molecules.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on provided source data. Limited financial and operational details for Alterola Biotech, Inc. are available. The company's 'OTC Other' tier and 'Unknown' disclosure status significantly limit comprehensive analysis.